Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events

BACKGROUND: Chemoradiotherapy followed by durvalumab is the standard treatment for the patients with local advanced non‐small cell lung cancer (NSCLC). There is a real‐world data about the management of adverse events, such as pneumonitis, according to the different institutions. Here, we present th...

Descripción completa

Detalles Bibliográficos
Autores principales: Miura, Yu, Mouri, Atsuto, Kaira, Kyoichi, Yamaguchi, Ou, Shiono, Ayako, Hashimoto, Kosuke, Nishihara, Fuyumi, Shinomiya, Shun, Akagami, Tomoe, Murayama, Yoshitake, Abe, Takanori, Noda, Shin‐ei, Kato, Shingo, Kobayashi, Kunihiko, Kagamu, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180558/
https://www.ncbi.nlm.nih.gov/pubmed/32160383
http://dx.doi.org/10.1111/1759-7714.13394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180558/
https://www.ncbi.nlm.nih.gov/pubmed/32160383
http://dx.doi.org/10.1111/1759-7714.13394

Ejemplares similares